rs4986893

Variant summary

Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BA1

The NM_000769.4(CYP2C19):​c.636G>A​(p.Trp212*) variant causes a stop gained change. The variant allele was found at a frequency of 0.00294 in 1,613,588 control chromosomes in the GnomAD database, including 214 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.0025 ( 13 hom., cov: 32)
Exomes 𝑓: 0.0030 ( 201 hom. )

Consequence

CYP2C19
NM_000769.4 stop_gained

Scores

1
1
5

Clinical Significance

drug response practice guideline B:1O:6

Conservation

PhyloP100: 4.14

Publications

673 publications found
Variant links:
Genes affected
CYP2C19 (HGNC:2621): (cytochrome P450 family 2 subfamily C member 19) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -8 ACMG points.

BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.0554 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CYP2C19NM_000769.4 linkc.636G>A p.Trp212* stop_gained Exon 4 of 9 ENST00000371321.9 NP_000760.1 P33261

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CYP2C19ENST00000371321.9 linkc.636G>A p.Trp212* stop_gained Exon 4 of 9 1 NM_000769.4 ENSP00000360372.3 P33261
ENSG00000276490ENST00000464755.1 linkn.*394G>A non_coding_transcript_exon_variant Exon 9 of 14 2 ENSP00000483243.1 A0A087X0B3
ENSG00000276490ENST00000464755.1 linkn.*394G>A 3_prime_UTR_variant Exon 9 of 14 2 ENSP00000483243.1 A0A087X0B3
CYP2C19ENST00000645461.1 linkn.1689G>A non_coding_transcript_exon_variant Exon 3 of 7

Frequencies

GnomAD3 genomes
AF:
0.00251
AC:
381
AN:
152056
Hom.:
11
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000362
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000524
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.0610
Gnomad SAS
AF:
0.00518
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000176
Gnomad OTH
AF:
0.00239
GnomAD2 exomes
AF:
0.00538
AC:
1351
AN:
251142
AF XY:
0.00507
show subpopulations
Gnomad AFR exome
AF:
0.000370
Gnomad AMR exome
AF:
0.000203
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0636
Gnomad FIN exome
AF:
0.0000925
Gnomad NFE exome
AF:
0.000246
Gnomad OTH exome
AF:
0.00261
GnomAD4 exome
AF:
0.00298
AC:
4362
AN:
1461412
Hom.:
201
Cov.:
31
AF XY:
0.00303
AC XY:
2204
AN XY:
727026
show subpopulations
African (AFR)
AF:
0.000538
AC:
18
AN:
33442
American (AMR)
AF:
0.000179
AC:
8
AN:
44674
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26116
East Asian (EAS)
AF:
0.0923
AC:
3662
AN:
39672
South Asian (SAS)
AF:
0.00340
AC:
293
AN:
86240
European-Finnish (FIN)
AF:
0.000131
AC:
7
AN:
53358
Middle Eastern (MID)
AF:
0.00139
AC:
8
AN:
5762
European-Non Finnish (NFE)
AF:
0.000101
AC:
112
AN:
1111770
Other (OTH)
AF:
0.00421
AC:
254
AN:
60378
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.483
Heterozygous variant carriers
0
202
404
606
808
1010
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
58
116
174
232
290
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00255
AC:
388
AN:
152176
Hom.:
13
Cov.:
32
AF XY:
0.00273
AC XY:
203
AN XY:
74362
show subpopulations
African (AFR)
AF:
0.000385
AC:
16
AN:
41550
American (AMR)
AF:
0.000523
AC:
8
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.0610
AC:
315
AN:
5168
South Asian (SAS)
AF:
0.00498
AC:
24
AN:
4824
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10550
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000176
AC:
12
AN:
68004
Other (OTH)
AF:
0.00614
AC:
13
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.511
Heterozygous variant carriers
0
17
34
52
69
86
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00555
Hom.:
875
Bravo
AF:
0.00267
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.000454
AC:
2
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.00549
AC:
667
Asia WGS
AF:
0.0460
AC:
160
AN:
3478
EpiCase
AF:
0.000218
EpiControl
AF:
0.000178

ClinVar

Significance: drug response
Submissions summary: Benign:1Other:6
Revision: practice guideline
LINK: link

Submissions by phenotype

not provided Benign:1Other:1
Aug 06, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 22865819, 20549256, 21855977, 22344438, 25087612, 25525159, 23874401, 7969038, 24906606) -

Dec 28, 2015
Eurofins Ntd Llc (ga)
Significance:other
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles).

Proguanil, poor metabolism of Other:1
Jun 01, 2009
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Mephenytoin, poor metabolism of Other:1
Jun 01, 2009
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Acute coronary syndrome Other:1
-
Cardiology Department, The First Affiliated Hospital of Nanjing Medical University
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:research

- decreased function

Clopidogrel response Other:1
-
Faculty of Pharmacy, Damascus University
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:research

rs4986893 is a SNP in the CYP2C19 gene and is linked to poor clopidogrel metabolic activation. rs4986893 is associated with reduced enzyme activity of CYP2C19 and lower concentration of clopidogrel active metabolite. likely responsive

CYP2C19: no function Other:1
-
Clinical Pharmacogenetics Implementation Consortium
Significance:drug response
Review Status:practice guideline
Collection Method:curation

- Allele function

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.069
T
BayesDel_noAF
Pathogenic
0.24
CADD
Pathogenic
35
DANN
Uncertain
0.98
Eigen
Benign
0.18
Eigen_PC
Benign
-0.13
FATHMM_MKL
Benign
0.052
N
PhyloP100
4.1
Vest4
0.79
GERP RS
3.3
Mutation Taster
=145/55
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4986893; hg19: chr10-96540410; COSMIC: COSV64907205; COSMIC: COSV64907205; API